Andere talen Radiopharm Theranostics Limited

Aandelen

RAD

AU0000181851

Beurs gesloten - Australian S.E. Andere beurzen 05:53:38 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,04 ^AUD	+2,56%		+11,11%	-45,95%

08/05	Radiopharm Theranostics komt aan bod tijdens gezondheidszorgevenementen georganiseerd door B. Riley Securities	MT
29/02	Radiopharm Theranostics doseert eerste patiënt in beeldvormingsstudie alvleesklierkanker	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities	08/05
Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study	29/02
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02
Radiopharm Theranostics Receives AU$1.9 Million Advance on R&D Tax Rebate	21/02
Radiopharm Secures Investment from US-based Lind Partners; Shares Decline 6%	06/02
Radiopharm Theranostics Raises AU$1.7 Million Via Shortfall Placement	24/01
Radiopharm Theranostics Secures Ethics Approval for Second Lung Cancer Trial Site	27/12
Radiopharm Theranostics to Start Phase One Lung Cancer Therapy Trial	26/12
Radiopharm Theranostics Raises AU$2.1 Million Via Entitlement Offer	08/12
28,046,696 Options of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	25/11
100,000,000 Ordinary Shares of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	25/11
Radiopharm Theranostics Secures AU$5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 4%	21/11
Radiopharm Theranostics Secures US FDA Approval for Phase 1 Pancreatic Cancer Diagnostic Trial	17-10-23
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer	09-10-23
Radiopharm Theranostics Secures Ethics Approval for Lung Cancer Trial; Shares Rise 4%	09-10-23
Radiopharm Theranostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31-08-23
Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer	24-08-23
Radiopharm welcomes positive guidance from FDA to advance Pivalate	31-05-23
Radiopharm Theranostics Secures US FDA Guidance for Clinical Trial of Imaging Drug in Brain Metastasis	29-05-23
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer	09-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Radiopharm Theranostics Limited

Aandelen

RAD

AU0000181851

Andere talen

Filters